Which 5-ASA?

Gut

Volumn 51, Issue 4, 2002, Pages 548-549

  Travis, Siman P L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE;

CANADA; CLINICAL TRIAL; COCHRANE LIBRARY; COLORECTAL CANCER; CONSTIPATION; CROHN DISEASE; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG MARKETING; DRUG MEGADOSE; DRUG METABOLISM; FRANCE; GERMANY; HUMAN; MAINTENANCE THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROCTITIS; RELAPSE; SHORT SURVEY; SUPPOSITORY; ULCERATIVE COLITIS; UNITED KINGDOM;

AMINOSALICYLIC ACIDS; COLITIS, ULCERATIVE; CROHN DISEASE; ENEMA; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; SULFASALAZINE; SUPPOSITORIES;

EID: 0036785349     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.51.4.548     Document Type: Short Survey

References (10)

1. Sutherland LR, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis (Cochrane review). In: The Cochrane Library, vol 1. Oxford: Update Software, 2002.
2. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of post-operative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000;118:264-73.
3. Laursen LS, Stokholm M, Bukhave K, et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values and urinary excretion. Gut 1990;31:1271-6.
4. Van Bodegraven AA, Boer RO, Lourens J, et al. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther 1996;10:327-32.
5. Gionchetti P, Rissole F, Ventura A, et al. Comparisan of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther 1997;11:1053-7.
6. Marteau P, Crand J, Foucault M, et al. Use of mesalazine slow-release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 1998;42:195-9.
7. Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis 1998;4:79-83.
8. Courtney M, Nunes D, Bergin C, et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992;339:1279-81.
9. Green JR, Gibson JA, Kerr GD, et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesolazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment Pharmacol Ther 1998;12:1207-16.
10. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145-53.